IkappaB-kinasebeta-dependent NF-kappaB Activation Provides Radioprotection to the Intestinal Epithelium
Overview
Authors
Affiliations
Acute injury to the intestinal mucosa is a major dose-limiting complication of abdominal radiation therapy. We studied the role of the transcription factor NF-kappaB in protection against radiation-induced apoptosis in the intestinal epithelium in vivo. We use mice in which NF-kappaB signaling through IkappaB-kinase (IKK)-beta is selectively ablated in intestinal epithelial cells to show that failure to activate epithelial cell NF-kappaB in vivo results in a significant increase in radiation-induced epithelial cell apoptosis. Furthermore, bacterial lipopolysaccharide, which is normally a radioprotective agent, is radiosensitizing in IKKbeta-deficient intestinal epithelial cells. Increased apoptosis in IKKbeta-deficient intestinal epithelial cells was accompanied by increased expression and activation of the tumor suppressor p53 and decreased expression of antiapoptotic Bcl-2 family proteins. These results demonstrate the physiological importance of the NF-kappaB system in protection against radiation-induced death in the intestinal epithelium in vivo and identify IKKbeta as a key molecular target for radioprotection in the intestine. Selective preactivation of NF-kappaB through IKKbeta in intestinal epithelial cells could provide a therapeutic modality that allows higher doses of radiation to be tolerated during cancer radiotherapy.
Liu F, Wei Y, Wang Z Turk J Med Sci. 2024; 53(6):1621-1634.
PMID: 38813508 PMC: 10760591. DOI: 10.55730/1300-0144.5731.
Salama V, Geng Y, Rigert J, Fuller C, Shete S, Moreno A Clin Transl Radiat Oncol. 2023; 43:100669.
PMID: 37954025 PMC: 10634655. DOI: 10.1016/j.ctro.2023.100669.
Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets.
Dai J, Tan X, Qiao H, Liu N Protein Cell. 2023; 15(4):239-260.
PMID: 37946397 PMC: 10984626. DOI: 10.1093/procel/pwad052.
The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer.
Yu I, Wu R, Tokumaru Y, Terracina K, Takabe K Cancers (Basel). 2022; 14(22).
PMID: 36428777 PMC: 9688177. DOI: 10.3390/cancers14225685.
Shao M, Yan Y, Zhu F, Yang X, Qi Q, Yang F Front Pharmacol. 2022; 13:849014.
PMID: 36120344 PMC: 9477143. DOI: 10.3389/fphar.2022.849014.